Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2018; 17: 74-80
Применение превентивного плевродеза у пациента с гистиоцитозом из клеток Лангерганса с поражением легких
https://doi.org/10.24287/1726-1708-2018-17-3-74-80Аннотация
Список литературы
1. Dimmler A., Geddert H., Werner M., Faller G. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch 2017; 470 (4): 429–35.
2. Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. European Respiratory Journal 2006; 27 (6): 1272–85.
3. Casolaro M.A., Bernaudin J.F., Saltini C., Ferrans V.J., Crystal R.G. Accumulation of Langerhans cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137 (2): 406–11.
4. Vassallo R., Ryu J.H. Pulmonary Langerhans’ cell histiocytosis. Clinics in Chest Medicine 2004; 25 (3): 561–71.
5. Suri H.S., Yi E.S., Nowakowski G.S., Vassallo R. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis 2012; 7 (1): 16.
6. Ronceray L., Pötschger U., Janka G., Gadner H., Minkov M. Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: Effect on course and outcome. J Pediatr 2012; 161 (1).
7. Roden A.C., Yi E.S. Pulmonary langerhans cell histiocytosis: An update from the pathologists’ perspective. Archives of Pathology and Laboratory Medicine 2016; 140 (3): 230–40.
8. Vassallo R., Ryu J.H., Schroeder D.R., Decker P.A., Limper A.H. Clinical Outcomes of Pulmonary Langerhans’-Cell Histiocytosis in Adults. N Engl J Med 2002; 346 (7): 484–90.
9. Abbott G.F., Rosado-de-Christenson M.L., Franks T.J., Frazier A.A., Galvin J.R. From the archives of the AFIP: pulmonary Langerhans cell histiocytosis. Radiographics 2004; 24 (3): 821–41.
10. Dauriat G., Mal H., Thabut G., Mornex J.F., Bertocchi M., Tronc F., et al. Lung transplantation for pulmonary langerhans’ cell histiocytosis: a multicenter analysis. Transplantation 2006; 81 (5): 746–50.
11. Baqir M., Vassallo R., Maldonado F., Yi E.S., Ryu J.H. Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchology Interv Pulmonol 2013; 20 (4): 309–12.
12. Berres M.L., Lim K.P., Peters T., Price J., Takizawa H., Salmon H., et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014; 211 (4): 669–83.
13. Elia D., Torre O., Cassandro R., Caminati A., Harari S. Pulmonary Langerhans cell histiocytosis: A comprehensive analysis of 40 patients and literature review. Eur J Intern Med 2015; 26 (5): 351–6.
14. Tazi A., Lorillon G., Haroche J., Neel A., Dominique S., Aouba A., et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis 2017; 12 (1): 95.
15. Lorillon G., Bergeron A., Detourmignies L., Jouneau S., Wallaert B., Frija J., et al. Cladribine is effective against cystic pulmonary langerhans cell histiocytosis. Am J Respir and Critical Care Medicine 2012; 186 (9): 930–2.
16. Weitzman S., Braier J., Donadieu J., Egeler R.M., Grois N., Ladisch S., et al. 2′-Chlorodeoxya-denosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009; 53 (7): 1271–6.
17. Lorillon G., Tazi A. How i manage pulmonary langerhans cell histiocytosis. Eur Respir Rev 2017; 26: 145.
18. Baumann M.H., Strange C., Heffner J.E., Light R., Kirby T.J., Klein J., et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119 (2): 590–602.
19. Bertrand P.C., Regnard J.F., Spaggiari L., Levi J.F., Magdeleinat P., Guibert L., et al. Immediate and long-term results after surgical treatment of primary spontaneous pneumothorax by VATS. Ann Thorac Surg 1996; 61 (6): 1641–45,
20. Lardinois D., Vogt P., Yang L., Hegyi I., Baslam M., Weder W. Non-steroidal anti-inflammatory drugs decrease the quality of pleurodesis after mechanical pleural abrasion. Eur J Cardio-thoracic Surgery 2004; 25 (5): 865–71.
21. Gossot D., Galetta D., Stern J.B., Debrosse D., Caliandro R., Girard P., et al. Results of thoracoscopic pleural abrasion for primary spontaneous pneumothorax. Surg Endosc Other Interv Tech 2004; 18 (3): 466–71.
22. Ciuche A., Nistor C., Pantile D., Marin D., Tudose A. Spontaneous pneumothorax in a case of pulmonary langerhans cell histiocytosis. Mædica 2011; 6 (3): 204–9.
23. Massard G., Thomas P., Wihlm J.M. Minimally invasive management for first and recurrent pneumothorax. Ann of Thoracic Surgery 1998; 66 (2): 592–9.
Pediatric Hematology/Oncology and Immunopathology. 2018; 17: 74-80
The use of preventive pleurodesis in patient with Langerhans-cell histiocytosis with lung involvement: the case report and the review
https://doi.org/10.24287/1726-1708-2018-17-3-74-80Abstract
Langerhans-cell histiocytosis (LCH) is a rare myeloid neoplasia (about 3 cases per 1 000 000 children yearly). Lung involvement is rare, usually as a part of multisystem disease. Clinically these lesions manifest with signs of respiratory insufficiency like dyspnea, cough and desaturation. Imaging shows nodules that are gradually transforming into thick- or thin-walled cysts. Rapture of these cysts leads to the pneumothorax which requires drainage. Our report shows clinical case of use of elective pleurodesis to prevent life-threatening complications of histologically confirmed LCH with lung involvement, which can develop either as a result of the disease or due to chemotherapy.
References
1. Dimmler A., Geddert H., Werner M., Faller G. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch 2017; 470 (4): 429–35.
2. Tazi A. Adult pulmonary Langerhans’ cell histiocytosis. European Respiratory Journal 2006; 27 (6): 1272–85.
3. Casolaro M.A., Bernaudin J.F., Saltini C., Ferrans V.J., Crystal R.G. Accumulation of Langerhans cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137 (2): 406–11.
4. Vassallo R., Ryu J.H. Pulmonary Langerhans’ cell histiocytosis. Clinics in Chest Medicine 2004; 25 (3): 561–71.
5. Suri H.S., Yi E.S., Nowakowski G.S., Vassallo R. Pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis 2012; 7 (1): 16.
6. Ronceray L., Pötschger U., Janka G., Gadner H., Minkov M. Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: Effect on course and outcome. J Pediatr 2012; 161 (1).
7. Roden A.C., Yi E.S. Pulmonary langerhans cell histiocytosis: An update from the pathologists’ perspective. Archives of Pathology and Laboratory Medicine 2016; 140 (3): 230–40.
8. Vassallo R., Ryu J.H., Schroeder D.R., Decker P.A., Limper A.H. Clinical Outcomes of Pulmonary Langerhans’-Cell Histiocytosis in Adults. N Engl J Med 2002; 346 (7): 484–90.
9. Abbott G.F., Rosado-de-Christenson M.L., Franks T.J., Frazier A.A., Galvin J.R. From the archives of the AFIP: pulmonary Langerhans cell histiocytosis. Radiographics 2004; 24 (3): 821–41.
10. Dauriat G., Mal H., Thabut G., Mornex J.F., Bertocchi M., Tronc F., et al. Lung transplantation for pulmonary langerhans’ cell histiocytosis: a multicenter analysis. Transplantation 2006; 81 (5): 746–50.
11. Baqir M., Vassallo R., Maldonado F., Yi E.S., Ryu J.H. Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchology Interv Pulmonol 2013; 20 (4): 309–12.
12. Berres M.L., Lim K.P., Peters T., Price J., Takizawa H., Salmon H., et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 2014; 211 (4): 669–83.
13. Elia D., Torre O., Cassandro R., Caminati A., Harari S. Pulmonary Langerhans cell histiocytosis: A comprehensive analysis of 40 patients and literature review. Eur J Intern Med 2015; 26 (5): 351–6.
14. Tazi A., Lorillon G., Haroche J., Neel A., Dominique S., Aouba A., et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis 2017; 12 (1): 95.
15. Lorillon G., Bergeron A., Detourmignies L., Jouneau S., Wallaert B., Frija J., et al. Cladribine is effective against cystic pulmonary langerhans cell histiocytosis. Am J Respir and Critical Care Medicine 2012; 186 (9): 930–2.
16. Weitzman S., Braier J., Donadieu J., Egeler R.M., Grois N., Ladisch S., et al. 2′-Chlorodeoxya-denosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009; 53 (7): 1271–6.
17. Lorillon G., Tazi A. How i manage pulmonary langerhans cell histiocytosis. Eur Respir Rev 2017; 26: 145.
18. Baumann M.H., Strange C., Heffner J.E., Light R., Kirby T.J., Klein J., et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119 (2): 590–602.
19. Bertrand P.C., Regnard J.F., Spaggiari L., Levi J.F., Magdeleinat P., Guibert L., et al. Immediate and long-term results after surgical treatment of primary spontaneous pneumothorax by VATS. Ann Thorac Surg 1996; 61 (6): 1641–45,
20. Lardinois D., Vogt P., Yang L., Hegyi I., Baslam M., Weder W. Non-steroidal anti-inflammatory drugs decrease the quality of pleurodesis after mechanical pleural abrasion. Eur J Cardio-thoracic Surgery 2004; 25 (5): 865–71.
21. Gossot D., Galetta D., Stern J.B., Debrosse D., Caliandro R., Girard P., et al. Results of thoracoscopic pleural abrasion for primary spontaneous pneumothorax. Surg Endosc Other Interv Tech 2004; 18 (3): 466–71.
22. Ciuche A., Nistor C., Pantile D., Marin D., Tudose A. Spontaneous pneumothorax in a case of pulmonary langerhans cell histiocytosis. Mædica 2011; 6 (3): 204–9.
23. Massard G., Thomas P., Wihlm J.M. Minimally invasive management for first and recurrent pneumothorax. Ann of Thoracic Surgery 1998; 66 (2): 592–9.
